The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class of drugs called glucagon-like peptide-1 agonists, or GLP-1.

(The Conversation) – Several years ago, a little-known drug named Ozempic – previously used only to treat diabetes – emerged as a promising new drug for weight management. The Food and Drug ...

A new study conducted by researchers from the University of Eastern Finland the Karolinska Institutet explored the ways that weight loss drugs like Ozempic and Wegovy can serve another purpose for ...

Novo Nordisk's stock (NVO) rose more than 8% in Friday trading on news that the company's latest weight-loss product delivered favorable results. The new drug, amycretin, similar to the company's ...

Data from the National Health and Nutrition Examination study show that between 2021-2023 ... And what about the new weight loss drugs? The Kaiser Family Foundation reported in its spring 2024 ...

The Biden administration moved Friday to negotiate the prices Medicare pays for the blockbuster weight-loss drugs ... of a new Medicare initiative aimed at lowering prescription drug prices ...

Weight-loss drugs have exploded in popularity - but a full understanding of everything they touch in the body is still coming together. "This is new territory," said lead researcher Dr Ziyad al ...

Novo Nordisk scored a much-needed win on Friday, with early-stage data on a new weight-loss drug that suggested it could work better than the obesity blockbusters already on the market.

Novo Nordisk (NYSE:NVO) shares are rallying 6.87% to $86.67 as of 10:27 AM ET Friday, after the company reported promising trial results for its new obesity drug ... to 22% weight loss over ...